DexCom up 4% in after-hours trading on quarterly bottom line beat
golfcphoto/iStock via Getty Images


DexCom (NASDAQ:DXCM) is up 4% in after-hours trading after the continuous glucose monitor company saw its Q4 2022 financial results beat on the bottom line.
Non-GAAP net income of $136.3M ($0.34 per diluted share) for the quarter compared to a net loss of $2.4M ($0.01) Q4 2021.

U.S. revenue grew 17%; international revenue was up 15% year over year. Overall revenue grew 17% to $815.2M in the quarter.
In addition, DexCom (DXCM) reiterated earlier 2023 guidance, including revenue of $3.35B-$3.49B vs $3.46B consensus, representing 15%-20% growth.
The company ended the quarter with cash and cash equivalents of $642.3M, a 39% drop from the year-ago period.
Read why Seeking Alpha contributor LD Investments rates DexCom (DXCM) a hold.